ReNeuron Group plc

Equities

RENE

GB00BF5G6K95

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:30:01 2024-02-05 am EST			5-day change	1st Jan Change
3.375 ^GBX	-2.17%		-.--%	-3.57%

May. 17	ReNeuron administrators in talks with potential investors	AN
May. 17	PetroTal buys Peru's Block 131 for USD5.0 million	AN

ReNeuron administrators in talks with potential investors

May 17, 2024 at 03:00 pm EDT

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Says Mark Smith and Stephen Cork of Cork Gully LLP, joint administrators, issue statement of proposals to the members and creditors of the group. The joint administrators say they have identified potential cornerstone investors. Talks are currently progressing with the potential investors. Joint administrators say they have cut costs by shedding staff. Joint administrators also send "teaser document" to 749 potentially interested parties. Joint administrators are currently negotiating and having positive discussions with multiple parties in relation to their interest in the business and/or assets of the group.

Current stock price: suspended at 3.28 pence

12-month change: down 55%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about ReNeuron Group plc

ReNeuron administrators in talks with potential investors	May. 17	AN
PetroTal buys Peru's Block 131 for USD5.0 million	May. 17	AN
ReNeuron Group Reports CFO Resignation	Apr. 17	MT
ReNeuron CFO steps down to pursue other opportunities	Apr. 17	AN
ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024	Apr. 17	CI
ReNeuron appoints administrators as rescue talks fail	Mar. 20	AN
ReNeuron Group to Appoint Administrators	Mar. 20	MT
ReNeuron warns; Gama Aviation pledges cash return	Feb. 05	AN
ReNeuron Group Suspends Share Trading in London Amid Financial Woes	Feb. 05	MT
ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024	Jan. 30	CI
ReNeuron interim loss narrows on lower costs; eyes partnerships	Nov. 08	AN
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Revenue GBP157,000	Nov. 08	MT
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Loss GBX-5.00	Nov. 08	MT
ReNeuron Group plc Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 08	CI
ReNeuron Group Reports In Vivo Data for Exosome Delivery Platform	23-09-04	MT
ReNeuron makes progress on exosome delivery platform	23-09-04	AN
ReNeuron Group plc Auditor Raises 'Going Concern' Doubt	23-06-15	CI
Transcript : ReNeuron Group plc, 2023 Earnings Call, May 25, 2023	23-05-25
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Revenue GBP530,000	23-05-25	MT
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Loss GBX-9.50	23-05-25	MT
ReNeuron Group plc Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-25	CI
ReNeuron Group plc Announces New Scientific Advisory Board	23-04-03	CI
FTSE 100 Closes Down 1.1% as Early Year Optimism Runs Into Turbulence	23-01-19	DJ
ReNeuron reduces headcount by 40%; to focus on CustomEX data	23-01-19	AN
Sterling Could Fall as BOE Stays Cautious	23-01-19	DJ

Chart ReNeuron Group plc

Duration

Period

More charts

Company Profile

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Sector

Biotechnology & Medical Research

Calendar

2024-07-10 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RENEURON GROUP PLC	-3.57%	2.46M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research